Cresco Labs Buys Laurel Harvest For $80 Million

Cresco Labs (CSE:CL) (OTCQX:CRLBF)  is buying Pennsylvania-based Laurel Harvest Labs, LLC  in a deal valued at $80 million. The acquisition is expected to close in Q4 of 2021.

Laurel Harvest has one of the eight original Chapter 20 licenses in Pennsylvania. The company comes with approximately 52,000 sq. ft. of indoor grow/processing space and room for an additional 52,000 sq. ft. of indoor cultivation space. there is one operational dispensary in Montgomeryville PA and a second dispensary in Scranton is currently under construction. Laurel Harvest also has the option to open an additional four dispensaries throughout the state.

“As the medical market continues to grow and as legislators develop plans for adult-use, we are increasing our depth in the key state of Pennsylvania to strengthen our wholesale leadership while growing profitability and scale through new retail. This acquisition will provide Cresco Labs with immediate incremental cultivation capacity, simplify our ability to expand production capacity further, and add six additional retail dispensary permits in the state,” said Charlie Bachtell, CEO of Cresco Labs. “Importantly, we are excited to further our commitment in research and development through one of the few Chapter 20 clinical registrant licenses in the state. Laurel Harvest and its academic clinical research partner, Temple University, have established one of the most sophisticated cannabis research programs in the country. As an organization focused on normalizing and professionalizing the cannabis industry, we sincerely look forward to supporting and expanding upon this research that will continue to help create safe, effective and accessible cannabis products.”

Located in a medical-only state, Laurel Harvest is very focused on helping patients and research. The company has an academic clinical research partnership with Lewis Katz School of Medicine at Temple University. It is also conducting six ongoing cannabis research studies. The company has said with regards to its scientific mission,

We aim to be at the forefront of advancing research, science, and policy relating to the clinical benefits, limitations and uses of cannabinoids through evidence-based medicine. We will dedicate our resources and expertise to help patients understand how cannabis can help them improve wellness through science. To give our healthcare professionals access to the most credible and current research to help you understand how cannabis can impact your health and wellness.

Cresco Labs will report financial results for the third quarter ended September 30th, 2021 on Thursday, November 11th, 2021 before the market opens.

Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 2 days

$MAPS WeedMaps Files For More Shares

@GreenMarketRpt – 3 days

Happy Friday! Here’s the week’s top news all bundled up in one quick Marijuana Money: December 2, 2021

Back to Top

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Monday morning.

We respect your privacy. See our privacy policy.